Product image of Nimotop (Nimodipine) supplied by GNH India

Nimotop

Active Ingredient:
Nimodipine
Origin:
EU

Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a sterile solution for intracisternal and intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients.
GNH India supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Laboratoire Xo

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nimotop is a cerebral vasodilator indicated for conditions involving post‑hemorrhagic cerebral vasospasm.

  • Cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits.
  • Aneurysmal subarachnoid hemorrhage: helps maintain cerebral perfusion during the critical vasospasm period.
  • Neurosurgical patients at risk of vasospasm: supports cerebral blood flow to limit secondary brain injury.

How It Works

  • Nimodipine selectively blocks L‑type calcium channels in vascular smooth muscle, especially within cerebral arteries. This inhibition reduces calcium influx, leading to relaxation of the vessel wall, vasodilation of intracranial vessels, and attenuation of vasospasm, thereby improving cerebral blood flow after hemorrhagic events.

Side Effects

Nimotop may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

  • Hypotension: transient drop in blood pressure.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: warm sensation with skin reddening.
  • Dizziness: sensation of light‑headedness.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Severe hypotension: may require medical intervention.
  • Myocardial infarction: rare cardiac event.
  • Hepatic dysfunction: elevated liver enzymes.
  • Allergic reaction: rash, pruritus, or anaphylaxis.
  • Stevens‑Johnson syndrome: severe skin eruption.
  • Seizures: uncommon neurologic event.

Precautions & Warnings

When using Nimotop, clinicians should observe specific safety measures.

  • Monitor blood pressure: watch for symptomatic hypotension.
  • Assess liver function: adjust use if hepatic impairment is present.
  • Avoid concurrent vasodilators: risk of additive blood pressure lowering.
  • Use caution in elderly patients: increased sensitivity to hemodynamic changes.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Nimotop can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Other calcium channel blockers: additive vasodilation may cause profound hypotension.
  • Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma concentrations.
  • Nitrates: combined effect can lead to severe blood pressure drops.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may enhance bradycardia and hypotension.
  • Diuretics: can affect electrolyte balance and blood pressure.
  • Other antihypertensives: may require dose adjustment to maintain target blood pressure.

Frequently Asked Questions

Nimotop contains nimodipine, a calcium channel blocker that is used to prevent cerebral vasospasm after subarachnoid hemorrhage. By dilating intracranial arteries, it helps maintain adequate blood flow to the brain during the critical post‑bleed period.

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral vessels. This reduces calcium entry, causing the vessels to relax and dilate, which counteracts the narrowing (vasospasm) that can follow a subarachnoid bleed.

The specific dose and administration schedule of Nimotop are determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals should follow local guidelines and product labeling.

Safety data for nimodipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nimotop (nimodipine) is the most widely studied calcium‑channel blocker for this indication and is specifically approved for preventing vasospasm after subarachnoid hemorrhage. Other agents, such as clazosentan or endothelin‑receptor antagonists, have different mechanisms and varying levels of clinical evidence.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Nimotop is supplied as a sterile solution for intracisternal or intravenous administration. The route, infusion rate, and duration are determined by the treating physician and are typically performed in a hospital or intensive‑care setting.

The most serious risks include severe hypotension, myocardial infarction, hepatic dysfunction, and rare allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt recognition and medical management are essential if these events occur.

Patients with known hypersensitivity to nimodipine or any component of the formulation should avoid Nimotop. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypotension, or those receiving interacting medications that could cause dangerous blood‑pressure drops.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT